All In Biotech

NDA 022549 · Nova Pneuma

Adasuve

Loxapine · Inhalation

Last checked: Nov 20, 2026Latest source record: Jan 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 21, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

28

5 Phase 3, 0 recruiting

FAERS reports

3,993

3,781 serious, 626 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: BRONCHOSPASM and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS WARNING: BRONCHOSPASM and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. ADASUVE can cause bronchospasm that has the potential to lead to respiratory distress and respiratory arrest, particularly in patients with lung diseases ( 4 , 5.1 ) ADASUVE is available only through a restricted program called the ADASUVE REMS ( 5.2 ) Administer ADASUVE only in a certified healthcare setting that has immediate access on site to supplies and healthcare professionals competent in the management of acute bronchospasm and access to emergency assistance for symptoms that require immediate medical attention. Certified healthcare settings must have a short-acting bronchodilator available for the immediate treatment of...

What it is approved for

From the label in effect Oct 1, 2026.

ADASUVE is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults [see Clinical Studies (14) ] . ADASUVE is an atypical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults ( 1 ). Limitations of Use: ADASUVE must be administered only in a certified healthcare setting ( 1 ). Limitations of Use: As part of the ADASUVE REMS Program to mitigate the risk of bronchospasm, ADASUVE must be administered only in a certified healthcare setting [see Warnings and Precautions (5.2) ] .

Mechanism: The mechanism of action of loxapine in the treatment of agitation associated with schizophrenia and bipolar I disorder is unclear. However, its efficacy could be mediated through a combination of antagonism of central serotonin and dopamine receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ADASUVE · LOXAPINE 10MG · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Loxapine" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective322
  • coma274
  • somnolence262
  • toxicity to various agents233
  • drug interaction225
  • weight increased219
  • poisoning deliberate215
  • off label use202
  • suicide attempt185
  • akathisia166
  • death163
  • neuroleptic malignant syndrome159

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
200513
200627
200726
200826
200920
201039
201154
201241
201335
201442
201581
201680
2017132
2018168
2019232
2020231
2021276
2022480
2023530
2024577
2025483
2026388

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 95 on PubMed

Sponsor: Nova Pneuma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.